Namaxir (Methotrexate)

Methotrexate, the active ingredient in Namaxir, is an antimetabolite (folate antagonist) presented as a sterile injectable for epidural, intra‑articular and intramuscular use. It is employed to treat rheumatoid arthritis, psoriasis, certain cancers and ectopic pregnancy. GNH USA supplies Namaxir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate is indicated for several disease groups where it modifies disease progression or eliminates abnormal cells. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: decreases skin plaque formation and severity. - Certain cancers (e.g., leukemia, lymphoma): interferes with rapid tumor cell proliferation. - Ectopic pregnancy: halts growth of trophoblastic tissue to allow non‑surgical resolution.

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Oral mucosal ulceration (mouth sores). - Transient elevation of liver enzymes. - Mild skin rash. - Decreased white blood cell count.

Serious or Rare Side Effects: - Severe hepatotoxicity or liver fibrosis. - Bone marrow suppression leading to pancytopenia. - Pulmonary fibrosis or interstitial pneumonitis. - Life‑threatening infections due to immunosuppression. - Acute renal failure. - Anaphylactic or severe hypersensitivity reactions.

Methotrexate requires careful monitoring and specific safety measures. - Liver monitoring: perform regular liver function tests to detect toxicity early. - Hematologic monitoring: check complete blood counts frequently to identify bone‑marrow suppression. - Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception for both sexes. - Renal function: adjust dose or avoid use in patients with impaired renal clearance. - Drug interactions: review concomitant medications that may increase toxicity. - Store at room temperature: keep in original packaging, protect from moisture and light.

Methotrexate interacts with several medicines that can alter its efficacy or safety profile.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity. - Trimethoprim‑sulfamethoxazole: potentiates bone‑marrow suppression. - Proton‑pump inhibitors (e.g., omeprazole): may raise methotrexate plasma levels. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine: additive immunosuppressive effect. - Sulfonamide antibiotics: may increase hematologic toxicity. - Phenytoin: can reduce methotrexate clearance. - Alcohol: exacerbates hepatic toxicity.